Table 1.
Characteristics of studies in stage 1 of the analysis.
| CHS | FHS | Rotterdam | AGES | TGEN | Mayo | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study design | Cohort | Cohort | Cohort | Cohort | Case-control | Case-control | ||||||
| Genotype platform | Illumina HumanCNV370-Duo® | Affymetrix GeneChip® Human Mapping 500K Array Set + 50K Gene Focused Panel® | Illumina Infinium HumanHap550-chip v3.0® | Illumina HumanCNV370-Duo® | Affymetrix GeneChip® Human Mapping 500K Array Set, | Illumina Human-Hap300v2-Duo BeadChips | ||||||
| Prevalence studies | Cases | Controls | Cases | Controls | Cases | Controls | Cases | Controls | Cases | Controls | Cases | Controls |
| N* | 93 | 2429 | 52 | 2091 | 171 | 5700 | 78 | 2684 | 829 | 536 | 810 | 1202 |
| Women (%) | 49 (53) | 1506 (62) | 42 (81) | 1192 (57) | 128 (75) | 3347 (59) | 39 (50) | 1557 (58) | 431 (52) | 338 (63) | 462 (57) | 601 (50) |
| Age | 80±6 | 75±5 | 87±6 | 76±7 | 84±9 | 69±9 | 81±5 | 76±5 | 81±10 | 80±7 | 73±4 | 74±5 |
| APOE e4 +ve (%) † | 35 (38) | 583 (24) | 20 (38) | 418 (20) | 62 (36) | 1549 (28) | 38 (49) | 725 (27) | 481 (58) | 107 (20) | 535 (66) | 337 (28) |
| Incidence studies | ||||||||||||
| Cohort at risk* | 2429 | 806 | 5700 | - | - | - | ||||||
| Women, % | 1506 (62) | 484 (60) | 3347 (59) | - | - | - | ||||||
| Ages at start (and at incident dementia) | 75±5 (82±5) | 82±6 (88±5) | 69±9 (82±7) | - | - | - | ||||||
| Incident AD cases | 435 | 76 | 462 | - | - | - | ||||||
| Mean follow-up (years) | 6.8±3.6 | 4.8±3.0 | 9.3±3.2 | - | - | - | ||||||
| APOE e4 +ve, %† | 632 (26) | 153 (19) | 1549 (28) | - | - | - | ||||||
In the prevalence studies, cases were those persons who suffered from AD at time of DNA draw. Controls were those that were free of any dementia. In the incidence studies, cases were those persons from the cohort at risk who developed dementia during the follow-up. Persons who developed another type of dementia were censored at the date of onset.
Data are means (SD), unless otherwise indicated. AGES=Age, Gene/Environment Susceptibility-Reykjavik Study, CHS=Cardiovascular Health Study, FHS=Framingham Heart Study, TGEN=Translational Genomics Research Institute.
Includes only those genotyped persons who also provided consent for these analyses and had high-quality genotyping (met QC-criteria), details are in the Supplement. In the FHS only Original cohort participants were included in incident analyses.
Among those with APOE genotyping available